Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: Results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study

Annals of the Rheumatic Diseases

Volumn 75, Issue 2, 2016, Pages 332-340

  Merrill, J T ^a   Van Vollenhoven, R F ^b   Buyon, J P ^c   Furie, R A ^d   Stohl, W ^e   Morgan Cox, M ^f   Dickson, C ^f   Anderson, P W ^f   Lee, C ^f   Berclaz, P Y ^f   Dorner T ^g  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f ELI LILLY AND COMPANY   (United States)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; DOUBLE STRANDED DNA ANTIBODY; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLATE MOFETIL; PLACEBO; PREDNISONE; TABALUMAB; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; B CELL ACTIVATING FACTOR; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY;

ADULT; AGED; ALLERGIC REACTION; ANAPHYLAXIS; ARTICLE; B LYMPHOCYTE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DEPRESSION; DISEASE EXACERBATION; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HERPES ZOSTER; HUMAN; INFECTION; INJECTION SITE REACTION; LOADING DRUG DOSE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY; OPPORTUNISTIC INFECTION; PHASE 3 CLINICAL TRIAL; PREGNANCY TERMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SLEDAI; SPONTANEOUS ABORTION; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE ATTEMPT; SYSTEMIC LUPUS ERYTHEMATOSUS; THRUSH; UNSPECIFIED SIDE EFFECT; ADOLESCENT; ANTAGONISTS AND INHIBITORS; BLACK PERSON; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; ETHNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; METABOLISM; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; BIOMARKERS; COMPLEMENT C3; COMPLEMENT C4; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84954302329     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-207654     Document Type: Article

References (25)

1. Tassiulas IO, Boumpas DT. Chapter 75: clinical features and treatment of systemic lupus erythematosus. In: Firestein GS, Budd RC, Harris ED Jr, et al., eds. Kelley's textbook of rheumatology. 8th edn. Philadelphia, PA: W.B. Saunders, 2008:1263-300.
2. Lopez R, Davidson JE, Beeby MD, et al. Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort. Rheumatology 2012;51:491-8.
3. Schneider P, MacKay F, Steiner V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999;189:1747-56.
4. Cancro MP, D'Cruz DP, Khamashta MA. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest 2009;119:1066-73.
5. Darce JR, Arendt BK, Wu X, et al. Regulated expression of BAFF-binding receptors during human B cell differentiation. J Immunol 2007;179:7272-86.
6. Stohl W, Metyas S, Tan S, et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus. Arthritis Rheum 2003;48:3475-86.
7. Petri M, Stohl W, Chatham W, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008;58:2453-9.
8. Navarra SV, Guzmán RM, Gallacher AE, et al., BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:721-31.
9. Furie R, Petri M, Zamani O, et al., BLISS-76 Study Group. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918-30.
10. Manetta J, Bina H, Ryan P, et al. Generation and characterization of tabalumab, a human monoclonal antibody that neutralizes both soluble and membrane-bound B-cell activating factor. J Inflamm Res 2014;7:121-31.
11. Hochberg M. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
12. Petri M, Kim MY, Kalunian KC, et al., OC-SELENA Trial. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005;353:2550-8.
13. Petri M, Buyon J, Kim M. Classification and definition of major flares in SLE clinical trials. Lupus 1999;8:685-91.
14. Wolfe F. Fatigue assessments in rheumatoid arthritis: comparative performance of visual analog scales and longer fatigue questionnaires in 7760 patients. J Rheumatol 2004;31:1896-902.
15. Mendoza TR, Wang XS, Cleeland CS, et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer 1999;85:1186-96.
16. Petri MA, van Vollenhoven RF, Buyon J, et al., BLISS-52 and BLISS-76 Study Groups. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials. Arthritis Rheum 2013;65:2143-53.
17. Wong W, Lan JL, Wang WC, et al. Serological studies on systemic lupus erythematosus. Chinese J Microbiol Immunol 1980;13:15-26.
18. Zonana-Nacach A, Salas M, Sanchez ML, et al. Measurement of clinical activity of systemic lupus erythematosus and laboratory abnormalities: a 12-month prospective study. J Rheumatol 1995;22:45-9.
19. Tseng CE, Buyon JP, Kim M, et al. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54:3623-32.
20. van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 2012;71:1343-9.
21. Krumbholz M, Meinl E. B cells in MS and NMO: pathogenesis and therapy. Semin Immunopathol 2014;36:339-50.
22. Meinl E, Derfuss T, Krumbholz M, et al. Humoral autoimmunity in multiple sclerosis. J Neurol Sci 2011;306:180-2.
23. Hopia L, Thangarajh M, Khademi M, et al. Cerebrospinal fluid levels of a proliferation-inducing ligand (APRIL) are increased in patients with neuropsychiatric systemic lupus erythematosus. Scand J Rheumatol 2011;40:363-72.
24. Crupi R, Cambiaghi M, Spatz L, et al. Reduced adult neurogenesis and altered emotional behaviors in autoimmune-prone B-cell activating factor transgenic mice. Biol Psychiatry 2010;67:558-66.
25. Tada S, Yasui T, Nakatsuji Y, et al. BAFF controls neural cell survival through BAFF receptor. PLoS ONE 2013;8:e70924.